Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.
Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Namba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nishii N, Fuke S, Yoshikawa M, Nakamura K, Ito H; MUSCAT-HF Study Investigators.
Ejiri K, et al. Among authors: akagi s.
Sci Rep. 2022 Sep 14;12(1):15449. doi: 10.1038/s41598-022-19371-6.
Sci Rep. 2022.
PMID: 36104378
Free PMC article.
Clinical Trial.